Novo Nordisk

Novo Nordisk

Novo NordiskNovo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Novo Nordisk RSS Channel

Filters
List of articles in category Novo Nordisk
Title Published Date
NovoEight® (turoctocog alfa) receives positive opinion from the European regulatory authorities 20 September 2013
Novo Nordisk files for regulatory approval of turoctocog alfa for haemophilia A 16 October 2012
Investigational insulin degludec shows 43% lower rates of night-time hypoglycaemia than insulin glargine 02 October 2012
Novo Nordisk receives positive opinion on recombinant factor XIII 28 May 2012
43 research talents awarded scholarships to help secure Denmark's future 25 January 2012
Positive opinion on the use of Levemir® in children with type 1 diabetes aged two to five years 23 September 2011
Greater overall patient satisfaction when switching from sitagliptin to Victoza® 13 September 2011
Novo Nordisk to build new corporate centre in Bagsværd, Denmark 25 August 2011
Novo Nordisk gains EU approval for FlexTouch® 15 July 2011
Novo Nordisk invests 1 billion Danish kroner in new factory in Denmark 22 June 2011
New clinical trial data support the use of Levemir® in children aged two to five years 23 March 2011
Novo Nordisk increased operating profit by 27% in 2010 07 February 2011
44 research talents get Novo scholarships to write their master theses 26 January 2011
Novo Nordisk's New Pen for Children - NovoPen Echo(R) - Wins GOOD DESIGN(TM) Award 19 January 2011
Novo Nordisk's NovoTwist(R) Wins GOOD DESIGN(TM) Award 09 January 2011
Novo Nordisk A/S and Emisphere Technologies, Inc. Announce Licence Agreement 21 December 2010
Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial 07 May 2010
The Lancet publishes new data demonstrating the superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin) 23 April 2010
Danish companies join forces to compete for global talent 12 February 2010
Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue 14 January 2010